BRAIN CANCER

Prostate Cancer

Lung Cancer

David M. Ashley, MBBS, FRACP, PhD, has been named director of the Preston Robert Tisch Brain Tumor Center at Duke University. His position began March 1, 2018, and he succeeded Darell Bigner, MD, PhD.

Lung Cancer

In results of a phase II study, cabozantinib (Cabometyx) showed signs of activity in patients with progressive glioblastoma who were naïve to antiangiogenic therapy, despite the predefined statistical target for success not being met.

Kenneth Aldape, MD, has joined the National Cancer Institute&rsquo;s Center for Cancer Research as chief of the Laboratory of Pathology, an integral component of the research and clinical community at the National Institutes of Health.<br /> &nbsp;

According to results of a phase I study recently published in&nbsp;<em>Journal of Clinical Oncology</em>, treatment with the investigational agent&nbsp;DNX-2401 resulted in 20% of patients with&nbsp;recurrent malignant glioma surviving more than 3 years from the time of treatment.

Treatment with lomustine plus bevacizumab provided a slightly improved progression-free survival, but did not demonstrate an overall survival advantage over treatment with lomustine alone in patients with progressive glioblastoma, according to results of a randomized phase III trial published in the<em> New England Journal of Medicine</em>.

A phase III clinical trial of VAL-083, a first-in-class small molecule chemotherapy agent, has opened for patients with glioblastoma multiforme whose disease has progressed during or after standard treatment with chemoradiation, according to a news release from Atlantic Health System. &nbsp;